During the last three months, 8 analysts shared their evaluations of Avantor AVTR, revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 6 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 1 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $25.88, a high estimate of $28.00, and a low estimate of $22.00. Observing a 19.43% increase, the current average has risen from the previous average price target of $21.67.
Investigating Analyst Ratings: An Elaborate Study
The perception of Avantor by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Luke Sergott | Barclays | Raises | Overweight | $27.00 | $24.00 |
| Andrew Cooper | Raymond James | Raises | Outperform | $26.00 | $22.50 |
| Conor McNamara | RBC Capital | Maintains | Outperform | $28.00 | - |
| Vijay Kumar | Evercore ISI Group | Raises | Outperform | $26.00 | $19.50 |
| Justin Bowers | Deutsche Bank | Raises | Hold | $22.00 | $20.00 |
| Luke Sergott | Barclays | Raises | Overweight | $24.00 | $21.00 |
| Dan Brennan | TD Cowen | Announces | Outperform | $28.00 | - |
| Matthew Sykes | Goldman Sachs | Raises | Buy | $26.00 | $23.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Avantor. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Avantor compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Avantor's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Avantor's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Avantor analyst ratings.
About Avantor
Avantor Inc is involved in providing products and services to biopharma, healthcare, education and government, and advanced technologies and applied materials industries. The company's offerings include materials and consumables, equipment and instrumentation and services and specialty procurement. Its brand profile consists of NuSil, RANKEM, POCH, BeneSphera, and Macron Fine Chemicals among others. The firm operates in three geographical segments namely Americas, Europe, and AMEA. It generates a majority of its revenue from the Americas.
Key Indicators: Avantor's Financial Health
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Avantor's revenue growth over 3 months faced difficulties. As of 30 September, 2023, the company experienced a decline of approximately -7.34%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Avantor's net margin excels beyond industry benchmarks, reaching 6.3%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Avantor's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.14%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Avantor's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.84% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Avantor's debt-to-equity ratio stands notably higher than the industry average, reaching 1.1. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Analyst Ratings: What Are They?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
